NONOF:OTCMKTS
Novo Nordisk A/S
38,38 $
arrow_downward
-0,72%(-0,28) 1 d.
28. sept., 16:00:00 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NONOF…
Atvērt
37,44 $
Augsta
38,85 $
Zema
37,44 $
Tirgus kapitalizācija
130,28 mljrd.
Vid. apjoms
132,42 tūkst.
Apjoms
11,18 tūkst.
Augstākā 52 ned.
64,75 $
Zemākā 52 ned.
34,00 $
Beta
0,63
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
37,44 $
Augsta
38,85 $
Zema
37,44 $
Tirgus kapitalizācija
130,28 mljrd.
Vid. apjoms
132,42 tūkst.
Apjoms
11,18 tūkst.
Augstākā 52 ned.
64,75 $
Zemākā 52 ned.
34,00 $
Beta
0,63
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Euronext Markets: Real-time Stock Market Data | live
·
pirms 48 minūtēm
Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill
Investing.com Australia
·
pirms 5 stundām
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal
Yahoo Finance
·
pirms 16 stundām
Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
TipRanks
·
pirms 18 stundām
Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme
Profils
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Novo's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com